Porfimer sodium is used in photodynamic therapy to treat certain types of cancer, particularly esophageal cancer and lung cancer. When activated by laser light, it helps destroy cancer cells while minimizing damage to healthy tissue.[2] Photofrin is currently approved and in use across 15 indications[4].[1]
Photofrin is one of 208 small molecule programs targeting Hilar Cholangiocarcinoma. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Competition
449 competitors in Non-Small Cell Lung Cancer
Photofrin
Navelbine
Pyrotinib
Ds-1062a
Remeron
Ftorafur
Aqupla
Valemetostat Tosylate
Treatment
Vibramycin
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Regulatory
Dec 27, 1995
PHOTOFRIN
NDA NDA020451
Sources
Details